RESHAPE: Non-interventional Study of Risperidone ISM® in Schizophrenia Patients Hospitalised Due to a Relapse
Study Details
Study Description
Brief Summary
This is a prospective, non-interventional, multicentre study designed to collect information about the effectiveness, safety and tolerability of Risperidone ISM in patients diagnosed with schizophrenia who are suffering an acute exacerbation, according to routine clinical practice.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
This is a non-interventional, multicentre, prospective study conducted in psychiatric inpatient units, and designed to collect information about the effectiveness, safety and tolerability of Risperidone ISM in patients diagnosed with schizophrenia and who are suffering an acute exacerbation, according to routine clinical practice.
The study will be conducted in five visits: the Baseline Visit is the day on which the patient fulfils the inclusion and exclusion criteria, including signature of the Informed Consent; two follow-up visits will be scheduled after the first injection of Risperidone ISM; in addition, there will be another visit on the day of discharge; and the Final Visit will occur approximately 28 days after the 2nd injection of Risperidone ISM.
The primary objective of the study is to assess, under usual clinical practice, the effectiveness of Risperidone ISM in patients hospitalised due to a schizophrenia relapse.
Approximately 1,200 adults' patients will be enrolled in the sites from the participating countries.
Study Design
Outcome Measures
Primary Outcome Measures
- Clinical Global Impression-Severity of Illness scale (CGI-S): change from baseline to Day 56. [Baseline and Day 56 (or the last post-baseline assessment)]
The Clinician Global Impression - Severity (CGI-S) score is a 7-point clinician-rated scale for assessing the global severity of the illness. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants". Negative change from baseline scores indicate improvement in the severity of illness whereas higher scores mean a worse outcome.
- Positive and Negative Syndrome Scale (PANSS-6): change from baseline to Day 56. [Baseline and Day 56 (or the last post-baseline assessment)]
The six-item version of the Positive and Negative Syndrome Scale (PANSS-6) is a 6-item scale derived from the full 30-item PANSS which evaluate: Delusions, Conceptual disorganization, Hallucinations, Blunted Affect, Social withdrawal and Lack of spontaneity and flow of conversation Safety and tolerability.
Secondary Outcome Measures
- Personal and Social Performance (PSP) scale [Baseline and Day 56 (or the last post-baseline assessment)]
The PSP is a 100-point single-item rating scale that is based on 4 areas: personal and social relationships; self-care; work and socially useful activities, and disturbing and aggressive behaviors. Each of the 4 domains is rated in 6 degrees of severity (absent, mild, manifest, marked, severe, very severe). Higher PSP scores indicate a better social functioning.
- Medication Satisfaction Questionnaire (MSQ) [Day 56 (or the last post-baseline assessment)]
The Medication Satisfaction Questionnaire (MSQ) is a single-item, global, patient-completed instrument designed to assess treatment satisfaction among patients with schizophrenia. It consists of 1 question: "Overall, how satisfied are you with your current antipsychotic medication(s)?" with responses assessed on a 7-point scale rated as follows: 1 = extremely dissatisfied, 2 = very dissatisfied, 3 = somewhat dissatisfied, 4 = neither satisfied nor dissatisfied, 5 = somewhat satisfied, 6 = very satisfied, 7 = extremely satisfied.
- Duration of hospitalisation [Baseline and Day 56 (or the last post-baseline assessment)]
The duration of hospitalisation is the time from admission in the hospital to discharge.
- Adverse drug reactions (ADR) [Up to Day 56 (or the last post-baseline assessment)]
An adverse drug reaction (ADR), is a response to a study treatment that is noxious and unintended and that occurs at doses normally used in man for prophylaxis, diagnosis or therapy of disease, or for the restoration, correction, or modification of physiological functions. Response in this context means that a causal relationship between a medicinal product and an adverse event is at least a reasonable possibility.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patient aged 18 years or older at the time of hospitalisation.
-
Patient with diagnosis of schizophrenia, as per clinical judgment.
-
Patient admitted to a psychiatric inpatient unit due to an acute exacerbation.
-
Patient has started treatment with Risperidone ISM within the previous 48 hours, according to the current Summary of Product Characteristics (SmPC).
-
Patient or their legal representative provides written informed consent to participate in the study.
Exclusion Criteria:
-
Patient with a diagnosis of schizoaffective disorder, bipolar disorder mental retardation, or other cognitive and neurodevelopmental disorders.
-
Patient with substance-induced psychosis or psychosis during intoxication (patients with comorbid substance abuse/dependence are allowed).
-
Patient unable to answer the study questionnaires.
-
Patient who is currently participating in another clinical study.
-
Patient pregnant or breast-feeding.
-
Patient with a serious and unstable medical condition, forensic patients, or patients with any contraindication mentioned in the SmPC of Risperidone ISM.
-
Patients currently on antipsychotic treatment with clozapine or any long-acting injectable antipsychotic.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Rovi Pharmaceuticals Laboratories
Investigators
- Study Chair: Christoph U Correll, Charite University, Berlin, Germany
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- ROV-RISP-2021-01